DRL to acquire select portfolio of UCB’s products business in India
The revenues of the acquired business is approximately Rs 150 crores for calendar year 2014
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Dr Reddy’s Laboratories
DRL in partnership with Hetero
To accelerate access to treatment for Hepatitis C in India
DRL opens formulation development laboratory
Dr. Reddy’s Laboratories’ (DRL) Custom Pharmaceutical Services (CPS) division has expanded its existing custom service facilities…
DRL with NICE Foundation launches Community Health Intervention Programme
DRL to contribute Rs 3.50 crores for this social programme
DRL closes acquisition of Habitrol brand from Novartis
Dr Reddy’s Laboratories (DRL) has closed the acquisition of Habitrol brand (an over-the-counter nicotine replacement therapy…
Dr Reddy’s, IPCA Labs products come under Canada govt scanner
Health Canada, the North American country’s food and drug regulator, has asked Canadian importers to quarantine health products…
DRL’s unit receives US FDA observations on possible lapses
The US Food and Drug Administration (US FDA) has found what it calls nine “inspectional observations” at Unit VI of Dr Reddy’s…
DRL closes acquisition of Habitrol brand from Novartis
Dr Reddy’s Laboratories (DRL) has closed the acquisition of Habitrol brand (an over-the-counter nicotine replacement therapy…
DRL launches docetaxel injection in US
Docetaxel injection USP, 20 mg/mL and 80 mg/4 mL are available as a single dose
Dr Reddy’s launch fexofenadine hydrochloride and pseudoephedrine hydrochloride extended release…
They are available in a 20 count blister